Product support
with OnePath®

Takeda’s OnePath program offers product support for your patients prescribed HYQVIA.
HYQVIA is indicated for the treatment of primary immunodeficiency (PI) in adults. HYQVIA is for subcutaneous use only. Safety and efficacy of chronic use of Recombinant Human Hyaluronidase in HYQVIA have not been established in conditions other than PI.
Takeda’s OnePath program offers product support for your patients prescribed HYQVIA.
Through OnePath, eligible patients are connected with a Patient Support Manager who can assist them by:
Facilitating an insurance benefits investigation
Working with specialty pharmacies to coordinate treatment access
Enrolling eligible* patients in the OnePath co-pay assistance program or providing information about other financial assistance options
Getting patients and caregivers started with in-home self-administration training, led by a specially trained nurse (if applicable)
Informing patients and caregivers about
educational resources available to them
The OnePath Co-Pay Assistance Program helps eligible patients cover certain out-of-pocket treatment costs.†
To enroll a patient in OnePath, complete a
HYQVIA Start Form with your patient and fax it to
1-833-388-5467.
For practices prescribing HYQVIA, we've developed training especially for nurses and conducted by our OnePath Clinical Educators on site or remotely.
This free resource is designed to provide the information and instruction necessary to administer HYQVIA.
This program is intended for healthcare providers who treat adult PI patients with HYQVIA, or who train other healthcare professionals in their facility who treat these patients.
The OnePath Clinical Educators program is not intended for patients.